KR920019819A - 입자를 형성하는 다수의 b형 간염 바이러스 표면 단백질 - Google Patents

입자를 형성하는 다수의 b형 간염 바이러스 표면 단백질 Download PDF

Info

Publication number
KR920019819A
KR920019819A KR1019920007143A KR920007143A KR920019819A KR 920019819 A KR920019819 A KR 920019819A KR 1019920007143 A KR1019920007143 A KR 1019920007143A KR 920007143 A KR920007143 A KR 920007143A KR 920019819 A KR920019819 A KR 920019819A
Authority
KR
South Korea
Prior art keywords
protein
hepatitis
pres1
virus
pres2
Prior art date
Application number
KR1019920007143A
Other languages
English (en)
Inventor
제이. 니스커 피서
해고피안 아피
부르케 파멜라
알. 쇼트 캐트린
Original Assignee
제침스 에프. 너턴
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제침스 에프. 너턴, 머크 앤드 캄파니, 인코포레이티드 filed Critical 제침스 에프. 너턴
Priority to JP51913593A priority Critical patent/JPH0796852B1/ja
Publication of KR920019819A publication Critical patent/KR920019819A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

입자를 형성하는 다수의 B형 간염 바이러스 표면 단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 HBsAg ORF, pGAL 10 프로모터, tADH1 터미네이터 및 pC1/1 기본 플라스미드중의 LEU2+선택성 마커를 함유하는 플라스미드 pKHBS-la의 도식적 도해이다,
제2도는 prsS1+preS2+S ORF, pGAL 10 프로모터, tADH1 터미네이터 및 pUEP24 기본 플라스미드중의 URA 선택성 마커를 함유하는 플라스미드 pKHBS-2a의 도식적 도해이다,
제3도는 pGAL 10 프로모터에 의해 구동되는 preS1+preS2+S ORE 및 pC1/1 기본 플라스미드 중의 pGAL1 프로모터로 구동되는 HBsAg ORE를 함유하는 양방향성 프로모 벡터인 플라스미드 pKHBS-3a의 도식적 도해이다.

Claims (23)

  1. 혼합된 입자를 형성하고 각각의 단백질에 대해 하나 이상의 항원성 에피토프(epitope)를 노출시키는 다수의 B형 간염 바이러스 단백질.
  2. 제1항에 있어서, adw, ayw, adr 또는 ayr혈청형의 다수의 S단백질 혈청형 ; 또는 preS1+preS2+S단백질 및 S단백질 ; 또는 preS1(Q4)preS2+S단백질 및 S단백질중에서 선택된 HBV 단백질를 함유하는 혼합된 입자.
  3. 제2항에 있어서, 입자가 S단백질의 보호적 "a" 에피토프를 노출시키는 혼합된 입자.
  4. 제2항에 있어서, S단백질 대 preS1+preS2+S단백질의 비율이 각각 약 1 : 20 및 20 : 1인 다수의 B형 간염 표면 단백질.
  5. 제4항에 있어서, S단백질 대 preS1+preS2+S단백질의 비율이 1 : 1, 3 : 1, 10 : 1 또는 20 : 1인 다수의 B형 간염 표면 단백질.
  6. 제2항에 있어서, 단백질들이 재조합 숙주 세포에서 동시에 생성되는 다수의 B형 간염 바이러스 표면 단백질.
  7. 제6항에 있어서, 재조합 숙주가 효모인 다수의 B형 간염 바이러스 표면 단백질.
  8. 제7항에 있어서, 효모 숙주가 단백질 글리코실화에 대해 유전적으로 결핍되는 다수의 B형 간염 바이러스 표면 단백질.
  9. 제8항에 있어서, 효모 숙주의 유전적 결핍이9 유전자에 존재하는 다수의 B형 간염 바이러스 표면 단백질.
  10. 제5항에 있어서, 정제된 입자의 탄수화물 대 단백질 비가 0.5 미만인 다수의 B형 간염 바이러스 표면 단백질.
  11. 제2항에 있어서, preS1+preS2+S단백질이 비-글리코실화 되는 다수의 B형 간염 바이러스 표면 단백질.
  12. 제11항에 있어서, preS1+preS2+S의 아미노산 서열이 글리코실화를 방지하도록 변형되는 다수의 B형 간염 바이러스 표면 단백질.
  13. 제12항에 있어서, preS1+psrS2+S단백질의 아미노산 변형이 preS1 아미노산 서열의 4위치에서 아스파라긴 대신 글루타민으로의 치환인 다수의 B형 간염 바이러스 표면 단백질.
  14. 제2항에 있어서, preS1+preS2+S단백질이 preS1 아미노산 서열의 4위치에서 아스파라긴 대신 글루타민으로의 아미노산 치환을 포함하고, S단백질 대 preS1+preS2+S단백질의 비율이 각각 약 1 : 20 내지 20 : 1인 다수의 B형 간염 바이러스 단백질.
  15. 제14항에 있어서, S단백질 대 preS1+preS2+S단백질의 비율이 각각 1 : 1, 3 : 1, 10 : 1 또는 20 : 1인 다수의 B형 간염 바이러스 단백질.
  16. 제14항에 있어서, 단백질이 재조합 숙주 세포에서 동시에 생성되는 다수의 B형 간염 바이러스 단백질.
  17. 제16항에 있어서, 재조합 숙주가 효모인 다수의 B형 간염 바이러스 단백질.
  18. 제17항에 있어서, 효모 숙주가 단백질 글리코실화에 대해 유전적으로 결핍되는 다수의 B형 간염 바이러스 단백질.
  19. 제18항에 있어서, 효모 세포의 유전적 결핍이9 유전자에 존재하는 다수의 B형 간염 바이러스 단백질.
  20. 제14항에 있어서, 정제된 입자의 탄수화물 대 단백질 비가 0.5미만인 다수의 B형 간염 바이러스 단백질.
  21. 제2항에 따른 입자를 함유하는 다수의 B형 간염 바이러스 표면 단백질을 포함하는 백신.
  22. 제20항에 따른 입자를 함유하는 다수의 B형 간염 바이러스 표면 단백질을 포함하는 백신.
  23. 진단시약의 개발에 사용하기 위한 제6항 또는 제9항 또는 제19항에 따른 항원 또는 면역원.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920007143A 1991-04-29 1992-04-28 입자를 형성하는 다수의 b형 간염 바이러스 표면 단백질 KR920019819A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP51913593A JPH0796852B1 (ko) 1992-04-28 1992-10-24

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69357591A 1991-04-29 1991-04-29
US07/693,575 1991-04-29

Publications (1)

Publication Number Publication Date
KR920019819A true KR920019819A (ko) 1992-11-20

Family

ID=24785226

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920007143A KR920019819A (ko) 1991-04-29 1992-04-28 입자를 형성하는 다수의 b형 간염 바이러스 표면 단백질

Country Status (19)

Country Link
EP (1) EP0511854A1 (ko)
JP (1) JPH06172392A (ko)
KR (1) KR920019819A (ko)
CN (1) CN1070685A (ko)
AU (1) AU1522792A (ko)
BG (1) BG98188A (ko)
CA (1) CA2067590A1 (ko)
CZ (1) CZ226993A3 (ko)
FI (1) FI934777A0 (ko)
HU (1) HUT67435A (ko)
IE (1) IE921386A1 (ko)
IL (1) IL101653A0 (ko)
MX (1) MX9202006A (ko)
NO (1) NO933895D0 (ko)
NZ (1) NZ242485A (ko)
SK (1) SK118293A3 (ko)
WO (1) WO1992019740A1 (ko)
YU (1) YU45292A (ko)
ZA (1) ZA923070B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341074C (en) 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
IL101651A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Hepatitis b virus surface proteins with reduced host carbohydrate content
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
EP1111061A1 (en) * 1999-12-20 2001-06-27 Universite Libre De Bruxelles Double selection vector
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
JP2010096677A (ja) * 2008-10-17 2010-04-30 Toray Ind Inc 抗体／抗原結合能を有する高感度免疫学測定用ナノ粒子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
JPS63230639A (ja) * 1987-03-19 1988-09-27 Nippon Chem Res Kk 新規なｂ型肝炎ウイルス表面抗原粒子とその製法
EP0288198A3 (en) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
EP0314096B1 (en) * 1987-10-29 1994-01-12 Zymogenetics, Inc. Methods of regulating protein glycosylation
EP0328123A1 (en) * 1988-02-09 1989-08-16 Eugene Tech International, Inc. Heterogeneous, pre-S rich hepatitis B surface antigen
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
ES2109921T3 (es) * 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
CA2022109A1 (en) * 1989-07-31 1991-02-01 Cheryl A. Schulman Enhanced expression of heterologous proteins in recombinant hosts in a non-growth media

Also Published As

Publication number Publication date
HU9303066D0 (en) 1994-01-28
NO933895L (no) 1993-10-28
SK118293A3 (en) 1994-03-09
BG98188A (en) 1994-06-30
IL101653A0 (en) 1992-12-30
NO933895D0 (no) 1993-10-28
CN1070685A (zh) 1993-04-07
YU45292A (sh) 1994-06-10
MX9202006A (es) 1992-11-01
HUT67435A (en) 1995-04-28
FI934777A (fi) 1993-10-28
JPH06172392A (ja) 1994-06-21
NZ242485A (en) 1993-11-25
IE921386A1 (en) 1992-11-04
AU1522792A (en) 1992-11-05
WO1992019740A1 (en) 1992-11-12
ZA923070B (en) 1992-12-30
EP0511854A1 (en) 1992-11-04
CA2067590A1 (en) 1992-10-30
FI934777A0 (fi) 1993-10-28
CZ226993A3 (en) 1994-04-13

Similar Documents

Publication Publication Date Title
André Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine
Heermann et al. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments
Theilmann et al. Detection of Pre–S1 Proteins in Serum and Liver of Hbsag–Positive Patients: A New Marker for Hepatitis B Virus Infection
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
GR3017804T3 (en) Hepatitis b vaccine.
Meisel et al. Fine mapping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus
Cabral et al. Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen
Madalinski et al. Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus.
KR920019819A (ko) 입자를 형성하는 다수의 b형 간염 바이러스 표면 단백질
Peterson The structure of hepatitis B surface antigen and its antigenic sites
Yerushalmi et al. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates
Fujisawa et al. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2+ S) protein particles (a third generation vaccine)
Bitter et al. Hepatitis B vaccine produced in yeast
Hellström et al. Absence of pre-S2 antibodies in natural hepatitis B virus infection
Geissler et al. Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations
Howard et al. Preparation and properties of immune-stimulating complexes containing hepatitis B virus surface antigen
Neurath et al. Detection of antiviral antibodies with predetermined specificity using synthetic peptide-β-lactamase conjugates: application to antibodies specific for the preS region of the hepatitis B virus envelope proteins
Neurath et al. Enzyme-linked immunoassay of pre-S gene-coded sequences in hepatitis B vaccines
KR920019373A (ko) 감소된 숙주 탄수화물 함량을 갖는 b형 간염 바이러스 표면 단백질
Gerlich Hepatitis B surface proteins
Waters et al. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies
Vento et al. Cellular immunity to nucleocapsid and pre-S determinants in asymptomatic carriers of hepatitis B virus.
Paul et al. Use of monoclonal antibodies to determine if HBsAg of mixed subtype is one particle or two
EP0241021A2 (en) Method of producing HBsAg containing amino acid sequence encoded by the late pre S region of HB virus and the said HBsAg
Haruna et al. Serum Pre-Sl and Pre-S2 Antigens as Prognostic Markers in Interferon Therapy for Chronic Hepatitis B

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid